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Background: CBT recipients may respond to post-transplant
vaccines differently than other transplant groups due to the
lack of transfer of donor immunity.
Methods: We analyzed vaccine responses in 48 CBT recipi-
ents transplanted at our center from 2005-2010 for the
treatment of hematologic malignancies with myeloablative
or non-myeloablative conditioning. GHVD ppx included
a calcineurin-inhibitor and MMF. All patients received
double unit CB grafts and no pt received ATG. Vaccination
criteria included CD4+ cell count > 200 cells/ul and IgG level
> 500 mg/dl at > 6 weeks following the last IVIG dose.
Results: Forty-eight of 69 (70%) eligible pts alive & disease-
free @ 12 months post-HCT were vaccinated. Vaccinated
patients engrafted with 6/6 (n ¼ 2), 5/6 (n ¼ 26), or 4/6 (n ¼
20) HLA-matched units. Twelve pts received rituximab
(median 4 doses) as planned peri-transplant therapy for B-
cell malignancies (n ¼ 6), EBV viremia/ lymphoma (n ¼ 3),
autoimmune hemolysis (n ¼ 1), pure red cell aplasia (n ¼ 1),
or recurrent disease (n¼1). Prior to immunization, 13
patients had no acute or chronic GVHDwhereas 35 had prior
grade II-IV acute and/or chronic GHVD. Overall, the median
time to vaccination was 16.9 months post-CBT; 18.9 months
in pts who received rituximab; 15.23 months in those who
did not (P¼ .056). Pre-vaccination titers obtained at amedian
of 1 yr demonstrated that> 85% of patients lacked protection
against pneumococcus, H. ﬂu, and pertussis and > 50%
lacked immunity against tetanus, measles, & mumps. Sero-
conversion or > 3- fold rise in titer was observed in > 60% of
patients in response to tetanus, diphtheria, H. ﬂu, polio and
pneumococcal (PCV7 or PCV13) vaccines. Following 3 doses
of rHBV vaccine, 52% pt seroconverted. Only 2/35 recipients
of a single Tdap developed protective pertussis titers; 0/8 pts
responded to a single protein-conjugated meninogoccal
vaccine. To date, 20 pts including 9 adults have received an
MMR at a median of 2.3 years post-CBT. 8 pts received the
live attenuated varicella vaccine. To date, seroconversion
following measles, mumps, & rubella vaccine occurred in
56%, 41% & 93% of pts, respectively and 5 evaluable pts
seroconverted after 1 (n¼3) or 2 doses of Varivax (n ¼ 2).
Survival in vaccinated patients is 100%. No serious reactions
to any vaccine occurred.
Conclusion: CBT recipients, including adults & those with
prior GVHD or rituximab therapy, are capable of responding
to tetanus, diphtheria, H. ﬂu, polio & PCV7 or PCV13 similar
to other transplant groups. The sub-optimal response to
pathogens associated with outbreaks in the community
(Hepatitis B, Pertussis, meningococcus, measles, mumps,
varicella) highlight the need to obtain pre- & post-vaccine
titers to document response, and the need to deﬁne the
optimal vaccination regimen in this population.191
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The rate of immune reconstitution (IR) is directly correlated
with thenumberofhematopoietic stemcells (HSC) infusedand
is particularly delayed in patients undergoing cord blood
transplantation (CBT) secondary to the limited numbers of
HSC. Thus, methods to increase the number of cord blood (CB)
progenitors have the potential to accelerate IR after CBT.
Natural killer (NK) cells play a crucial role in early IR after HCT
because they are the ﬁrst lymphocyte subset to recover after
transplant. CB NK cells have been reported to have incomplete
maturation and require activation for effective function. Here,
we report a clinically relevant method for ex vivo expansion of
NKcells isolated fromCBwithout theuseof a stromal layer.Our
group has demonstrated that CB NK cells cultured in the
presence of IL-2 and IL-15 results in amulti-log increase in the
number of precursors that have a signiﬁcant increase in cyto-
toxicity against several target cancer cell lines. After 21 days in
culture, there is a 1.848 0.341 log fold increase in the number
of CD3-CD56+ NK cells (range, 0.420 to 3.108) (P < .001, N¼9).
After culture, we also found a signiﬁcant 2.612 0.310 log fold
increase (range, 0.979 to 3.622) (P< .001, N¼9) in the number
of CD3+CD56+ NKT cells. Evaluation of cytotoxicity against
K562cells, a chronicmyelogenous leukemia, showedtherewas
also a signiﬁcant increase in cytolytic function at days 14 (31.52
 8.317% target cell lysis, P< .01, N¼8) and 21 (44.22 9.866%
target cell lysis, P< .01, N¼8) in culturewhen compared to day
of isolation; similar results were seen using Jurkat cells, an
acute T-cell lymphoblastic leukemia (T-ALL). Evaluation of NK
cell resistant cells lines was also tested. While we found an
increase in cytotoxicity toward the myeloid lymphoid
leukemia cell line (MLL), MV411, after culture, the RS411 (MLL/
ALL) and HDLM2 (Hodgkin's lymphoma) cell lines remained
resistant to cytolytic killing (N¼3). Currently, we are investi-
gating the NK cell population(s) responsible for the cytotoxic
killing and the corresponding killer cell Ig-like receptor (KIR)
ligand/adhesion molecule(s) that may be responsible for
function. We hypothesize that using methods to increase the
number of CB NK cells have the potential to prevent early
relapse, infections and graft versus host disease, as well as
facilitate engraftment when administered following CBT.
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Tissue engineering approaches based on implantation of
biomimetic three-dimensional (3D) tissue constructs have
been used for more than a decade for in vivo regeneration of
